All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Macimorelin
Therapeutic Area: Endocrinology Product Name: Macrilen
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Consilient Health
Deal Size: Undisclosed Upfront Cash: $1.2 million
Deal Type: Licensing Agreement December 07, 2020
Details:
CH will be responsible for obtaining pricing and reimbursement approval in the European economic area and the U.K, and bearing the regulatory cost for the label extension for pediatric use pending successful outcome of the upcoming study of macimorelin in diagnosis of CGHD
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: ORMD-0801
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2020
Details:
Oramed has screened the first patients in its global Phase 3 trials of its oral insulin capsule ORMD-0801 to treat type 2 diabetes. Both Phase 3 trials, ORA-D-013-1 and ORA-D-013-2, will treat T2D patients who have inadequate glycemic control over a period of 6 to 12 months.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Imeglimin Hydrochloride
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Sumitomo Dainippon Pharma Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2020
Details:
Metavant has conducted a strategic review and has decided not to move forward with the development of Imeglimin. Metavant will actively explore options for a potential out-licensing of Imeglimin rights for a period of 60 day.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Macimorelin
Therapeutic Area: Endocrinology Product Name: Macrilen
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $11.0 million Upfront Cash: $6.1 million
Deal Type: Licensing Agreement November 16, 2020
Details:
Aeterna continues to retain all rights to macimorelin outside of the U.S. and Canada but, in demonstration of Novo Nordisk’s continued commitment to macimorelin, Novo Nordisk has agreed to make an immediate upfront payment to Aeterna of €5 million.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sotagliflozin
Therapeutic Area: Endocrinology Product Name: Zynquista
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
Sotagliflozin significantly reduced total cardiovascular deaths, heart failure hospitalization and urgent visits, achieving primary endpoint in both studies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Product Name: LY3298176
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
Eli Lilly and Company will conduct a webcast to provide an overview of the tirzepatide Phase 3 type 2 diabetes clinical trial program in preparation for five future Phase 3 top-line data disclosures.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Teplizumab
Therapeutic Area: Endocrinology Product Name: PRV-031
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
Teplizumab is an anti-CD3 monoclonal antibody (mAb). The BLA has been submitted for Teplizumab for prevention of clinical type one diabetes (T1D) in at-risk individuals with the submission of the chemistry, manufacturing and controls and administrative information modules.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Product Name: Tlando
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020
Details:
Results from the previously completed dose validation ("DV") study of a fixed dose TLANDO in hypogonadal males will also be presented at the meeting.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Teplizumab
Therapeutic Area: Endocrinology Product Name: PRV-031
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
Teplizumab is an anti-CD3 monoclonal antibody (mAb) being developed for the interception, delay, or prevention of type 1 diabetes (T1D).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Levoketoconazole
Therapeutic Area: Endocrinology Product Name: Recorlev
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering September 16, 2020
Details:
The Company intends to use the net proceeds to continue development and regulatory activities, facilitate commercial readiness and commercially launch Recorlev primarily in the US, support the life cycle management activities of Keveyis and for general corporate purposes.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
